Clinical trial characteristics sorted by groups A, B, and C
| . | Group A (n = 46), n (%) . | Group B (n = 244), n (%) . | Group C (n = 27), n (%) . | Total (N = 317), n (%) . |
|---|---|---|---|---|
| Phase | ||||
| 1/2 | 7 (15.3) | 50 (20.0) | 2 (7.4) | 59 (19.0) |
| 2 | 25 (54.3) | 173 (71.0) | 22 (81.5) | 220 (69.0) |
| 2/3 | 2 (4.3) | 4 (2.0) | 1 (3.7) | 7 (2.0) |
| 3 | 12 (26.1) | 17 (7.0) | 2 (7.4) | 31 (10.0) |
| Status | ||||
| Completed | 20 (43.5) | 116 (47.0) | 12 (44.5) | 148 (47.0) |
| Terminated | 5 (10.9) | 36 (15.0) | 5 (18.5) | 46 (15.0) |
| Ongoing | 6 (13.0) | 21 (9.0) | 2 (7.4) | 29 (9.0) |
| Unknown | 6 (13.0) | 22 (9.0) | 3 (11.1) | 31(10.0) |
| Recruiting | 5 (10.9) | 39 (16.0) | 5 (18.5) | 49 (15.0) |
| Withdrawn before enrollment | 3 (6.5) | 7 (3.0) | 0 (0.0) | 10 (3.0) |
| Not yet recruiting | 1 (2.2) | 3 (1) | 0 (0.0) | 4 (1.0) |
| Disease focus | ||||
| MDS only | 44 (95.7) | 148 (61.0) | 19 (70.3) | 211 (67.0) |
| AML, CMML, or other hematologic malignancies | 2 (4.3) | 96 (39.0) | 8 (29.7) | 106 (33.0) |
| Therapy used | ||||
| HMAs | 7 (15.2) | 67 (27.0) | 12 (44.4) | 86 (27.0) |
| Novel agents | 5 (10.9) | 30 (13.0) | 2 (7.4) | 37 (12.0) |
| Growth factors | 17 (37.0) | 29 (12.0) | 2 (7.4) | 48 (15.0) |
| Oral Chemotherapy | 13 (28.3) | 76 (31.0) | 9 (33.3) | 98 (31.0) |
| Others | 4 (8.7) | 42 (17.0) | 2 (7.4) | 48 (15.0) |
| . | Group A (n = 46), n (%) . | Group B (n = 244), n (%) . | Group C (n = 27), n (%) . | Total (N = 317), n (%) . |
|---|---|---|---|---|
| Phase | ||||
| 1/2 | 7 (15.3) | 50 (20.0) | 2 (7.4) | 59 (19.0) |
| 2 | 25 (54.3) | 173 (71.0) | 22 (81.5) | 220 (69.0) |
| 2/3 | 2 (4.3) | 4 (2.0) | 1 (3.7) | 7 (2.0) |
| 3 | 12 (26.1) | 17 (7.0) | 2 (7.4) | 31 (10.0) |
| Status | ||||
| Completed | 20 (43.5) | 116 (47.0) | 12 (44.5) | 148 (47.0) |
| Terminated | 5 (10.9) | 36 (15.0) | 5 (18.5) | 46 (15.0) |
| Ongoing | 6 (13.0) | 21 (9.0) | 2 (7.4) | 29 (9.0) |
| Unknown | 6 (13.0) | 22 (9.0) | 3 (11.1) | 31(10.0) |
| Recruiting | 5 (10.9) | 39 (16.0) | 5 (18.5) | 49 (15.0) |
| Withdrawn before enrollment | 3 (6.5) | 7 (3.0) | 0 (0.0) | 10 (3.0) |
| Not yet recruiting | 1 (2.2) | 3 (1) | 0 (0.0) | 4 (1.0) |
| Disease focus | ||||
| MDS only | 44 (95.7) | 148 (61.0) | 19 (70.3) | 211 (67.0) |
| AML, CMML, or other hematologic malignancies | 2 (4.3) | 96 (39.0) | 8 (29.7) | 106 (33.0) |
| Therapy used | ||||
| HMAs | 7 (15.2) | 67 (27.0) | 12 (44.4) | 86 (27.0) |
| Novel agents | 5 (10.9) | 30 (13.0) | 2 (7.4) | 37 (12.0) |
| Growth factors | 17 (37.0) | 29 (12.0) | 2 (7.4) | 48 (15.0) |
| Oral Chemotherapy | 13 (28.3) | 76 (31.0) | 9 (33.3) | 98 (31.0) |
| Others | 4 (8.7) | 42 (17.0) | 2 (7.4) | 48 (15.0) |
HMA, hypomethylating agent.